Drug Patent Watch

NOVEMBER 24, 2024

Patient centricity has become a crucial aspect of the pharmaceutical industry, particularly in the development of generic drugs. Here, we will explore the best practices in patient centricity for generic drug development… Source

Generic Drugs 98

Generic Drugs Development Drugs 98

Bio Pharma Dive

SEPTEMBER 30, 2022

The drug, which will be sold as Relyvrio, showed modest benefits in function and survival in testing. It also became the latest test of the FDA's flexibility toward new therapies for neurological disorders.

Drugs 364

Drugs Development 364

Drug Patent Watch

DECEMBER 10, 2024

The pharmaceutical industry has undergone significant changes over the past decade, with a growing trend towards outsourcing key aspects of research, development, and manufacturing to third-party vendors. The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48

Manufacturing 96

Manufacturing Development Drugs Compliance 96

Bio Pharma Dive

NOVEMBER 13, 2023

How can these increase the probability of success or efficiency in a pre-clinical and clinical drug development program? Regulatory agencies have set the framework and use cases for RWE.

Development 265

Development Drugs 265

Drug Patent Watch

JANUARY 23, 2025

The Future of Generic Drug Development: Opportunities and Challenges for Emerging Markets As the global healthcare landscape continues to evolve, emerging markets are playing an increasingly important role in shaping the future of generic drug development. Share your thoughts in the comments below!

Generic Drugs 85

Generic Drugs Marketing Development Drugs 85

Pharmaceutical Technology

SEPTEMBER 8, 2022

Tetra Bio-Pharma and Cellvera have entered an agreement to jointly develop ARDS-003 as an oral combination therapeutic candidate with 400mg Qifenda (Favipiravir) for Covid-19. A first-in-human drug product, ARDS-003 contains the active pharmaceutical agent, Onternabez. Qifenda is a broad-spectrum antiviral drug in the commercial stage.

Development 331

Development RNA Containment Drugs 331

Drug Patent Watch

JANUARY 14, 2025

The Generic Drug Revolution: Setting the Stage Before we dive into the nitty-gritty, let’s take a moment to appreciate the impact of generic drugs. Did you know that generic drugs now make up about 90% of all prescription drug purchases in the United States, while accounting for only 20% of prescription drug spending[1]?

Generic Drugs 87

Generic Drugs Development Drugs Manufacturing 87

Bio Pharma Dive

MAY 2, 2022

The regulator cited concerns around single-country trials in turning back Hutchmed's pancreatic cancer treatment, while manufacturing issues held up Junshi and Coherus' throat cancer medicine.

Development 319

Development Regulation Manufacturing Drugs 319

Bio Pharma Dive

NOVEMBER 14, 2022

The deal, which could carry a total value of roughly $145 million, is in large part focused on a nasal formulation of the opioid overdose drug nalmefene.

Development 359

Development Drugs 359

Bio Pharma Dive

FEBRUARY 2, 2024

The California biotech is the third this year to go public, following stock offerings from CG Oncology and Arrivent Biopharma.

Development 315

Development Drugs 315

Bio Pharma Dive

OCTOBER 30, 2023

The venture firm has supported a number of approved medicines with its co-development strategy, including Pfizer’s Besponsa and Apellis’ Empaveli.

Development 264

Development Medicine Drugs 264

Pharmaceutical Technology

SEPTEMBER 13, 2022

Novo Nordisk has signed a new strategic partnership with Microsoft to expedite the discovery and development of drugs leveraging big data and artificial intelligence (AI). The AI models developed out of the partnership will be utilised for a variety of use cases, of which the initial two are underway.

Drugs 348

Drugs Big Data Development Research 348

Bio Pharma Dive

JANUARY 13, 2025

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar depression.

Drugs 246

Drugs Development 246

Bio Pharma Dive

MARCH 7, 2023

As many as a third of FDA-approved drugs target GPCRs in some fashion, with uses ranging from treating cancer to pain. But biotech startups say there is still room to develop more.

Protein 360

Protein FDA Approval Drugs Development 360

Bio Pharma Dive

OCTOBER 14, 2024

The deal would hand Lundbeck a treatment for a series of rare brain disorders that could, by the company's estimates, become a blockbuster product.

Development 281

Development Drugs Production 281

Bio Pharma Dive

MARCH 28, 2023

The biotech is working on a dual-acting weight loss treatment that could compete with medicines from Novo Nordisk, Eli Lilly and others.

Development 315

Development Medicine Drugs 315

Bio Pharma Dive

NOVEMBER 9, 2022

While many companies are still unsure of the Inflation Reduction Act's effects, some have begun to warn investors about the likelihood of lower sales and reduced profitability.

Sales 311

Sales Development Drugs 311

Bio Pharma Dive

DECEMBER 8, 2022

As the success of drugs like Enhertu catalyzes new investment in antibody-drug conjugates, the California startup is launching with plans to develop more potent versions of the targeted cancer medicines.

Drugs 323

Drugs Antibody Medicine Development 323

Bio Pharma Dive

SEPTEMBER 16, 2022

The public-private partnership plans to bring together scientific experts, private entities and patient groups to better understand certain neurodegenerative disorders and find new treatments.

Development 352

Development Drugs 352

Bio Pharma Dive

NOVEMBER 21, 2023

The partnership is another investment by the biotech subsidiary in artificial intelligence for drug discovery and development, continuing an industry trend.

Drugs 315

Drugs Development 315

Bio Pharma Dive

NOVEMBER 14, 2023

The Series A round for three-year-old startup VectorY is one of the largest private financings in Europe this year, Forbion said.

Development 286

Development Drugs 286

Bio Pharma Dive

JUNE 2, 2022

Backed by $200 million in funding and led by biotech veteran Samantha Truex, Upstream is developing a clinical-stage inflammatory disease drug acquired from Astellas last year.

Drugs 333

Drugs Research Development 333

Bio Pharma Dive

OCTOBER 6, 2023

The funding, which is part of ACT for ALS, will support expanded access studies of drugs developed by Prilenia Therapeutics, Clene Nanomedicine and Rapa Therapeutics.

Drugs 305

Drugs Research Development 305

Pharmaceutical Technology

OCTOBER 19, 2022

Akouos focuses on developing adeno-associated viral gene therapies to treat inner ear conditions, including sensorineural hearing loss. It has combined expertise in otology, gene therapy and inner ear drug delivery to meet the requirements of individuals with disabling hearing loss globally.

Gene Therapy 298

Gene Therapy Gene Development Genetics 298

Pharmaceutical Technology

FEBRUARY 19, 2025

MSK plans to speed up early-stage drug development by using AWS Drug Discovery Workbench to screen potential candidates.

Drugs 273

Drugs Development 273

Bio Pharma Dive

JULY 20, 2022

The deal, which is worth $60 million upfront, broadens Vertex’s reach into gene editing and expands Verve’s research beyond heart disease.

Gene Editing 323

Gene Editing Gene Development Drugs 323

Bio Pharma Dive

NOVEMBER 21, 2024

The startup, Pep2Tango, is combining four methods of accelerating weight loss into one medicine in the hopes of developing a treatment that can improve upon drugs like Wegovy and Zepbound.

Drugs 294

Drugs Medicine Development 294

Pharmaceutical Technology

MARCH 13, 2025

Vivace Therapeutics has closed $35m in a Series D financing round to support the clinical development of its cancer drug VT3989.

Development 147

Development Drugs Clinical Development 147

Pharmaceutical Technology

MARCH 14, 2025

Insilico Medicine has completed a Series E round, raising $110m to progress the development of its pipeline of drugs and AI platform.

Development 147

Development Drugs Medicine 147

Bio Pharma Dive

APRIL 3, 2024

The startup claims to have a more efficient way to develop biologic drugs that treat disease by turning on cellular pathways, rather than blocking them.

Antibody 280

Antibody Drugs Development 280

Bio Pharma Dive

SEPTEMBER 12, 2024

The biotech will now suspend development of a drug prospect that Sanofi acquired partial rights to just four months ago.

Drugs 280

Drugs Development 280

Pharmaceutical Technology

AUGUST 21, 2024

Dr Reddy's Laboratories, Aurigene Pharmaceutical and Kainomyx signed an MoU to co-develop and co-commercialise an anti-malarial drug.

Development 219

Development Drugs 219

Drug Patent Watch

MARCH 12, 2025

The Unseen Heroes of Generic Drugs: Stability Testing 101 As a consumer, have you ever stopped to think about the rigorous process that goes into bringing a generic version of your favorite medication to market? For generic drug manufacturers, stability testing is a critical step in the development process.

Generic Drugs 97

Generic Drugs Drugs Manufacturing Branding 97

AuroBlog - Aurous Healthcare Clinical Trials blog

AUGUST 5, 2024

The Drug Discovery & Development Workshop 2024 is set to be a cornerstone event for professionals and students in the pharmaceutical and biotechnology sectors.

Development 188

Development Drugs Clinical Trials Clinical Trials 188

Bio Pharma Dive

JUNE 20, 2024

Interim study data suggest the Danish drugmaker can remain in the race to develop new kinds of weight loss drugs as doctors seek alternatives to the now dominant GLP-1s.

Drugs 272

Drugs Doctor Doctors Trials 272